Nonalcoholic fatty liver disease and obstructive sleep apnea

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1124-1135

  Aron Wisnewsky, Judith ^a,b,c   Clement, Karine ^a,b,c   Pépin, Jean Louis ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

Chronic intermittent hypoxia; Nonalcoholic fatty liver disease; Obstructive sleep apnea

Indexed keywords

PROTEIN LYSINE 6 OXIDASE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ARTICLE; CHILDHOOD OBESITY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXPERIMENTAL STEATOHEPATITIS; EXTRACELLULAR MATRIX; FATTY LIVER; GENE EXPRESSION; HUMAN; INTESTINE; INTESTINE MUCOSA PERMEABILITY; LIPID PEROXIDATION; LIPOGENESIS; LIVER; LIVER INJURY; META ANALYSIS (TOPIC); METABOLIC DISORDER; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDERED BREATHING; COMPLICATION; INSULIN RESISTANCE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY;

HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN RESISTANCE; LIPOGENESIS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84978836002     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.05.004     Document Type: Article

References (101)

1. [1] Ogden, CL, Carroll, MD, Flegal, KM, Prevalence of obesity in the United States. JAMA 312:2 (2014), 189–190.
2. [2] Kopelman, PG, Obesity as a medical problem. Nature 404:6778 (2000), 635–643.
3. [3] Rosenzweig, I, Glasser, M, Polsek, D, Leschziner, GD, Williams, SCR, Morrell, MJ, Sleep apnoea and the brain: A complex relationship. Lancet Respir Med 3:5 (2015), 404–414.
4. [4] Young, T, Shahar, E, Nieto, FJ, Redline, S, Newman, AB, Gottlieb, DJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: The Sleep Heart Health Study. Arch Intern Med 162:8 (2002), 893–900.
5. [5] Baguet, J-P, Barone-Rochette, G, Tamisier, R, Levy, P, Pépin, J-L, Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol 9:12 (2012), 679–688.
6. [6] Malhotra, A, Patil, S, Sands, S, Ayas, N, Central sleep apnoea in congestive heart failure. Lancet Respir Med 3:7 (2015), 507–508.
7. [7] Tasali, E, Ip, MSM, Obstructive sleep apnea and metabolic syndrome: Alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 5:2 (2008), 207–217.
8. [8] Jullian-Desayes, I, Joyeux-Faure, M, Tamisier, R, Launois, S, Borel, A-L, Levy, P, et al. Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: A systematic review from sham CPAP randomized controlled trials. Sleep Med Rev 21 (2015), 23–38.
9. [9] Ip, MSM, Lam, B, Ng, MMT, Lam, WK, Tsang, KWT, Lam, KSL, Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 165:5 (2002), 670–676.
10. [10] Arnaud, C, Dematteis, M, Pepin, J-L, Baguet, J-P, Lévy, P, Obstructive sleep apnea, immuno-inflammation, and atherosclerosis. Semin Immunopathol 31:1 (2009), 113–125.
11. [11] Health Quality Ontario, Oral appliances for obstructive sleep apnea: An evidence-based analysis. Ont Health Technol Assess Ser 9:5 (2009), 1–51.
12. [12] Chirinos, JA, Gurubhagavatula, I, Teff, K, Rader, DJ, Wadden, TA, Townsend, R, et al. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med 370:24 (2014), 2265–2275.
13. [13] Tuomilehto, H, Seppä, J, Uusitupa, M, Obesity and obstructive sleep apnea–clinical significance of weight loss. Sleep Med Rev 17:5 (2013), 321–329.
14. [14] Grunstein, RR, Stenlöf, K, Hedner, JA, Peltonen, M, Karason, K, Sjöström, L, Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 30:6 (2007), 703–710.
15. [15] Spicuzza, L, Caruso, D, Di Maria, G, Obstructive sleep apnoea syndrome and its management. Ther Adv Chronic Dis 6:5 (2015), 273–285.
16. [16] Chalasani, N, Younossi, Z, Lavine, JE, Diehl, AM, Brunt, EM, Cusi, K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:7 (2012), 1592–1609.
17. [17] Younossi, ZM, Koenig, AB, Abdelatif, D, Fazel, Y, Henry, L, Wymer, M, Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology, 2015.
18. [18] American Gastroenterological Association, American Gastroenterological Association medical position statement: Nonalcoholic fatty liver disease. Gastroenterology 123:5 (2002), 1702–1704.
19. [19] Brunt, EM, Janney, CG, Di Bisceglie, AM, Neuschwander-Tetri, BA, Bacon, BR, Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 94:9 (1999), 2467–2474.
20. [20] Kleiner, DE, Brunt, EM, Van Natta, M, Behling, C, Contos, MJ, Cummings, OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:6 (2005), 1313–1321.
21. [21] Cohen, JC, Horton, JD, Hobbs, HH, Human fatty liver disease: Old questions and new insights. Science 332:6037 (2011), 1519–1523.
22. [22] Brunt, EM, Kleiner, DE, Wilson, LA, Belt, P, Neuschwander-Tetri, BA, NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology 53:3 (2011), 810–820.
23. [23] Bedossa, P, Poitou, C, Veyrie, N, Bouillot, J-L, Basdevant, A, Paradis, V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:5 (2012), 1751–1759.
24. [24] Ratziu, V, Massard, J, Charlotte, F, Messous, D, Imbert-Bismut, F, Bonyhay, L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 6, 2006, 6.
25. [25] Poynard, T, Ratziu, V, Charlotte, F, Messous, D, Munteanu, M, Imbert-Bismut, F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 6, 2006, 34.
26. [26] Roulot, D, Czernichow, S, Le Clésiau, H, Costes, J-L, Vergnaud, A-C, Beaugrand, M, Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. J Hepatol 48:4 (2008), 606–613.
27. [27] Day, CP, James, OF, Steatohepatitis: A tale of two “hits”?. Gastroenterology 114:4 (1998), 842–845.
28. [28] Neuschwander-Tetri, BA, Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 52:2 (2010), 774–788.
29. [29] Li, J, Thorne, LN, Punjabi, NM, Sun, C-K, Schwartz, AR, Smith, PL, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 97:7 (2005), 698–706.
30. [30] Lévy, P, Bonsignore, MR, Eckel, J, Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 34:1 (2009), 243–260.
31. [31] Dematteis, M, Godin-Ribuot, D, Arnaud, C, Ribuot, C, Stanke-Labesque, F, Pépin, J-L, et al. Cardiovascular consequences of sleep-disordered breathing: Contribution of animal models to understanding the human disease. ILAR J 50:3 (2009), 262–281.
32. [32] Savransky, V, Bevans, S, Nanayakkara, A, Li, J, Smith, PL, Torbenson, MS, et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 293:4 (2007), G871–G877.
33. [33] Drager, LF, Li, J, Reinke, C, Bevans-Fonti, S, Jun, JC, Polotsky, VY, Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. Obesity (Silver Spring) 19:11 (2011), 2167–2174.
34. [34] Jouët, P, Sabaté, J-M, Maillard, D, Msika, S, Mechler, C, Ledoux, S, et al. Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: A prospective study. Obes Surg 17:4 (2007), 478–485.
35. [35] Daltro, C, Cotrim, HP, Alves, E, de Freitas, LA, Araújo, L, Boente, L, et al. Nonalcoholic fatty liver disease associated with obstructive sleep apnea: Just a coincidence?. Obes Surg 20:11 (2010), 1536–1543.
36. [36] Türkay, C, Ozol, D, Kasapoğlu, B, Kirbas, I, Yıldırım, Z, Yiğitoğlu, R, Influence of obstructive sleep apnea on fatty liver disease: Role of chronic intermittent hypoxia. Respir Care 57:2 (2012), 244–249.
37. [37] Sookoian, S, Pirola, CJ, Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: A meta-analysis. Obes Surg 23:11 (2013), 1815–1825.
38. [38] Agrawal, S, Duseja, A, Aggarwal, A, Das, A, Mehta, M, Dhiman, RK, et al. Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center. Hepatol Int 9:2 (2015), 283–291.
39. [39] Campos, GM, Bambha, K, Vittinghoff, E, Rabl, C, Posselt, AM, Ciovica, R, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47:6 (2008), 1916–1923.
40. [40] Tanné, F, Gagnadoux, F, Chazouillères, O, Fleury, B, Wendum, D, Lasnier, E, et al. Chronic liver injury during obstructive sleep apnea. Hepatology 41:6 (2005), 1290–1296.
41. [41] Gholam, PM, Flancbaum, L, Machan, JT, Charney, DA, Kotler, DP, Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102:2 (2007), 399–408.
42. [42] Kunde, SS, Lazenby, AJ, Clements, RH, Abrams, GA, Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42:3 (2005), 650–656.
43. [43] Ulitsky, A, Ananthakrishnan, AN, Komorowski, R, Wallace, J, Surapaneni, SN, Franco, J, et al. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg 20:6 (2010), 685–691.
44. [44] Polotsky, VY, Patil, SP, Savransky, V, Laffan, A, Fonti, S, Frame, LA, et al. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 179:3 (2009), 228–234.
45. [45] Mishra, P, Nugent, C, Afendy, A, Bai, C, Bhatia, P, Afendy, M, et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int 28:8 (2008), 1080–1086.
46. [46] Petta, S, Marrone, O, Torres, D, Buttacavoli, M, Cammà, C, Di Marco, V, et al. Obstructive sleep apnea is associated with liver damage and atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One, 10(12), 2015, e0142210, 10.1371/journal.pone.0142210 [eCollection 2015].
47. [47] Aron-Wisnewsky, J, Minville, C, Tordjman, J, Lévy, P, Bouillot, J-L, Basdevant, A, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 56:1 (2012), 225–233.
48. [48] Mesarwi, OA, Shin, M-K, Drager, LF, Bevans-Fonti, S, Jun, JC, Putcha, N, et al. Lysyl oxidase as a serum biomarker of liver fibrosis in patients with severe obesity and obstructive sleep apnea. Sleep, 2015.
49. [49] Minville, C, Hilleret, M-N, Tamisier, R, Aron-Wisnewsky, J, Clement, K, Trocme, C, et al. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea. Chest 145:3 (2014), 525–533.
50. [50] Qi, J-C, Huang, J-C, Lin, Q-C, Zhao, J-M, Lin, X, Chen, L-D, et al. Relationship between obstructive sleep apnea and nonalcoholic fatty liver disease in nonobese adults. Sleep Breath, 2015.
51. [51] Lin, Q-C, Chen, L-D, Chen, G-P, Zhao, J-M, Chen, X, Huang, J-F, et al. Association between nocturnal hypoxia and liver injury in the setting of nonalcoholic fatty liver disease. Sleep Breath 19:1 (2015), 273–280.
52. [52] Musso, G, Cassader, M, Olivetti, C, Rosina, F, Carbone, G, Gambino, R, Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 14:5 (2013), 417–431.
53. [53] Corey, KE, Misdraji, J, Zheng, H, Malecki, KM, Kneeman, J, Gelrud, L, et al. The absence of obstructive sleep apnea may protect against non-alcoholic fatty liver in patients undergoing bariatric surgery. PLoS One, 8(5), 2013, e62504.
54. [54] Schwimmer, JB, Deutsch, R, Kahen, T, Lavine, JE, Stanley, C, Behling, C, Prevalence of fatty liver in children and adolescents. Pediatrics 118:4 (2006), 1388–1393.
55. [55] Molleston, JP, Schwimmer, JB, Yates, KP, Murray, KF, Cummings, OW, Lavine, JE, et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 164:4 (2014), 707–713.e3.
56. [56] Della, CC, Vajro, P, Socha, P, Nobili, V, Pediatric non-alcoholic fatty liver disease: Recent advances. Clin Res Hepatol Gastroenterol 38:4 (2014), 419–422.
57. [57] Patton, HM, Sirlin, C, Behling, C, Middleton, M, Schwimmer, JB, Lavine, JE, Pediatric nonalcoholic fatty liver disease: A critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 43:4 (2006), 413–427.
58. [58] Kheirandish-Gozal, L, Sans Capdevila, O, Kheirandish, E, Gozal, D, Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest 133:1 (2008), 92–99.
59. [59] Alkhouri, N, Kheirandish-Gozal, L, Matloob, A, Alonso-Álvarez, ML, Khalyfa, A, Terán-Santos, J, et al. Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea. Sleep Med 16:9 (2015), 1031–1035.
60. [60] Nobili, V, Cutrera, R, Liccardo, D, Pavone, M, Devito, R, Giorgio, V, et al. Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med 189:1 (2014), 66–76.
61. [61] Sundaram, SS, Sokol, RJ, Capocelli, KE, Pan, Z, Sullivan, JS, Robbins, K, et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr 164:4 (2014), 699–706.e1.
62. [62] Nobili, V, Alisi, A, Cutrera, R, Carpino, G, De Stefanis, C, D'Oria, V, et al. Altered gut-liver axis and hepatic adiponectin expression in OSAS: Novel mediators of liver injury in paediatric non-alcoholic fatty liver. Thorax 70:8 (2015), 769–781.
63. [63] Reinke, C, Bevans-Fonti, S, Drager, LF, Shin, M-K, Polotsky, VY, Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J Appl Physiol 111:3 (2011), 881–890.
64. [64] Hubbi, ME, Hu, H, null, K, Ahmed, I, Levchenko, A, GL, S, Chaperone-mediated autophagy targets hypoxia-inducible factor-1α (HIF-1α) for lysosomal degradation. J Biol Chem 288:15 (2013), 10703–10714.
65. [65] Polotsky, VY, Li, J, Punjabi, NM, Rubin, AE, Smith, PL, Schwartz, AR, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 552:Pt 1 (2003), 253–264.
66. [66] Shin, M-K, Drager, LF, Yao, Q, Bevans-Fonti, S, Yoo, D-Y, Jun, JC, et al. Metabolic consequences of high-fat diet are attenuated by suppression of HIF-1α. PLoS One, 7(10), 2012, e46562.
67. [67] Drager, LF, Li, J, Shin, M-K, Reinke, C, Aggarwal, NR, Jun, JC, et al. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. Eur Heart J 33:6 (2012), 783–790.
68. [68] Li, J, Bosch-Marce, M, Nanayakkara, A, Savransky, V, Fried, SK, Semenza, GL, et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. Physiol Genomics 25:3 (2006), 450–457.
69. [69] Pamidi, S, Tasali, E, Obstructive sleep apnea and type 2 diabetes: Is there a link?. Front Neurol, 3, 2012, 126.
70. [70] Vgontzas, AN, Papanicolaou, DA, Bixler, EO, Hopper, K, Lotsikas, A, Lin, HM, et al. Sleep apnea and daytime sleepiness and fatigue: Relation to visceral obesity, insulin resistance, and hypercytokinemia. J C lin Endocrinol Metab 85:3 (2000), 1151–1158.
71. [71] Drager, LF, Lopes, HF, Maki-Nunes, C, Trombetta, IC, Toschi-Dias, E, Alves, MJNN, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One, 5(8), 2010, e12065.
72. [72] Trzepizur, W, Le Vaillant, M, Meslier, N, Pigeanne, T, Masson, P, Humeau, MP, et al. Independent association between nocturnal intermittent hypoxemia and metabolic dyslipidemia. Chest 143:6 (2013), 1584–1589.
73. [73] Paschetta, E, Belci, P, Alisi, A, Liccardo, D, Cutrera, R, Musso, G, et al. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm, 2015, 2015, 815721.
74. [74] Li, J, Grigoryev, DN, Ye, SQ, Thorne, L, Schwartz, AR, Smith, PL, et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol 99:5 (2005), 1643–1648.
75. [75] Sun, K, Halberg, N, Khan, M, Magalang, UJ, Scherer, PE, Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction. Mol Cell Biol 33:5 (2013), 904–917.
76. [76] Liu, Y, Aron-Wisnewsky, J, Marcelin, G, Genser, L, Le Naour, G, Torcivia, A, et al. Accumulation and changes in composition of collagens in subcutaneous adipose tissue after bariatric surgery. J Clin Endocrinol Metab 101:1 (2016), 293–304.
77. [77] Jun, J, Savransky, V, Nanayakkara, A, Bevans, S, Li, J, Smith, PL, et al. Intermittent hypoxia has organ-specific effects on oxidative stress. Am J Phys Regul Integr Comp Phys 295:4 (2008), R1274–R1281.
78. [78] Savransky, V, Nanayakkara, A, Vivero, A, Li, J, Bevans, S, Smith, PL, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 45:4 (2007), 1007–1013.
79. [79] Savransky, V, Reinke, C, Jun, J, Bevans-Fonti, S, Nanayakkara, A, Li, J, et al. Chronic intermittent hypoxia and acetaminophen induce synergistic liver injury in mice. Exp Physiol 94:2 (2009), 228–239.
80. [80] Denko, NC, Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:9 (2008), 705–713.
81. [81] Regueira, T, Lepper, PM, Brandt, S, Ochs, M, Vuda, M, Takala, J, et al. Hypoxia inducible factor-1 alpha induction by tumour necrosis factor-alpha, but not by toll-like receptor agonists, modulates cellular respiration in cultured human hepatocytes. Liver Int 29:10 (2009), 1582–1592.
82. [82] Koshikawa, N, Hayashi, J-I, Nakagawara, A, Takenaga, K, Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. J Biol Chem 284:48 (2009), 33185–33194.
83. [83] Aron-Wisnewsky, J, Gaborit, B, Dutour, A, Clement, K, Gut microbiota and non-alcoholic fatty liver disease: New insights. Clin Microbiol Infect 19:4 (2013), 338–348.
84. [84] Kheirandish-Gozal, L, Peris, E, Wang, Y, Tamae Kakazu, M, Khalyfa, A, Carreras, A, et al. Lipopolysaccharide-binding protein plasma levels in children: Effects of obstructive sleep apnea and obesity. J Clin Endocrinol Metab 99:2 (2014), 656–663.
85. [85] Pépin, J-L, Tamisier, R, Lévy, P, Obstructive sleep apnoea and metabolic syndrome: Put CPAP efficacy in a more realistic perspective. Thorax 67:12 (2012), 1025–1027.
86. [86] Coughlin, SR, Mawdsley, L, Mugarza, JA, Wilding, JPH, Calverley, PMA, Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 29:4 (2007), 720–727.
87. [87] Hoyos, CM, Killick, R, Yee, BJ, Phillips, CL, Grunstein, RR, Liu, PY, Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: A randomised sham-controlled study. Thorax 67:12 (2012), 1081–1089.
88. [88] West, SD, Nicoll, DJ, Wallace, TM, Matthews, DR, Stradling, JR, Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 62:11 (2007), 969–974.
89. [89] Hecht, L, Möhler, R, Meyer, G, Effects of CPAP-respiration on markers of glucose metabolism in patients with obstructive sleep apnoea syndrome: A systematic review and meta-analysis. Ger Med Sci, 9, 2011, Doc20.
90. [90] Chin, K, Nakamura, T, Takahashi, K, Sumi, K, Ogawa, Y, Masuzaki, H, et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med 114:5 (2003), 370–376.
91. [91] Kohler, M, Stradling, JR, Does continuous positive airway pressure therapy improve non-alcoholic fatty liver disease?. Respirology 21:2 (2016), 209–210.
92. [92] Kohler, M, Pepperell, JCT, Davies, RJO, Stradling, JR, Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: Data from a randomized controlled trial. Respiration 78:2 (2009), 141–146.
93. [93] Jullian-Desayes, I, Tamisier, R, Zarski, J-P, Aron-Wisnewsky, J, Launois-Rollinat, SH, Trocme, C, et al. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials. Respirology 21:2 (2016), 378–385.
94. [94] Lassailly, G, Caiazzo, R, Buob, D, Pigeyre, M, Verkindt, H, Labreuche, J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149:2 (2015), 379–388 [quiz e15–6].
95. [95] Shai, I, Spence, JD, Schwarzfuchs, D, Henkin, Y, Parraga, G, Rudich, A, et al. Dietary intervention to reverse carotid atherosclerosis. Circulation 121:10 (2010), 1200–1208.
96. [96] Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L, Torres-Gonzalez, A, Gra-Oramas, B, Gonzalez-Fabian, L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:2 (2015), 367–378.e5 [quiz e14–5].
97. [97] Dyson, PA, The therapeutics of lifestyle management on obesity. Diabetes Obes Metab 12:11 (2010), 941–946.
98. [98] Wing, RR, Phelan, S, Long-term weight loss maintenance. Am J Clin Nutr 82:1 Suppl. (2005), 222S–225S.
99. [99] Bamberga, M, Rizzi, M, Gadaleta, F, Grechi, A, Baiardini, R, Fanfulla, F, Relationship between energy expenditure, physical activity and weight loss during CPAP treatment in obese OSA subjects. Respir Med 109:4 (2015), 540–545.
100. [100] Aron-Wisnewsky, J, Pepin, J-L, New insights in the pathophysiology of chronic intermittent hypoxia-induced NASH: The role of gut-liver axis impairment. Thorax 70:8 (2015), 713–715.
101. [101] Pulixi, EA, Tobaldini, E, Battezzati, PM, D'Ingianna, P, Borroni, V, Fracanzani, AL, et al. Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease. PLoS One, 9(4), 2014, e96349.